Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients
Purpose The aim of this analysis was to compare the biochemical no evidence of disease (bNED) rates in low-risk prostate cancer patients treated at two centers of excellence using different approaches: seed brachytherapy (BT) and external beam radiotherapy (EBRT). Materials and methods A total of 91...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 2012-04, Vol.188 (4), p.305-310 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 310 |
|---|---|
| container_issue | 4 |
| container_start_page | 305 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 188 |
| creator | Goldner, G. Pötter, R. Battermann, J.J. Schmid, M.P. Kirisits, C. Sljivic, S. van Vulpen, M. |
| description | Purpose
The aim of this analysis was to compare the biochemical no evidence of disease (bNED) rates in low-risk prostate cancer patients treated at two centers of excellence using different approaches: seed brachytherapy (BT) and external beam radiotherapy (EBRT).
Materials and methods
A total of 919 low-risk prostate cancer patients, treated from 1998–2008, were identified in the two databases. In Utrecht, 667 patients received I-125 BT applying a dose of 144 Gy. In Vienna, 252 patients were treated with EBRT, applying a local dose of 70 Gy in 82 patients and 74 Gy in 170 patients. bNED rates (Phoenix definition) were assessed.
Results
The median follow-up was 46 months (range 1–148 months). The 5-year actuarial bNED rates were 94% for BT patients and 88% for EBRT patients (p = 0.002)—84% for patients receiving 70 Gy and 91% for patients receiving 74 Gy, respectively. In the univariate analysis, patients receiving 70 Gy showed significantly worse outcome compared to BT (p = 0.001) and a difference close to significance compared to 74 Gy (p = 0.06). In the multivariate analysis including tumor stage, Gleason score, initial PSA, hormonal therapy, and dose, patients receiving 70 Gy EBRT showed significantly worse bNED rates compared to BT patients.
Conclusion
Low-risk prostate cancer patients receiving 74 Gy by EBRT show comparable biochemical control rates to patients receiving seed brachytherapy, whereas patients receiving 70 Gy show significantly worse outcome. |
| doi_str_mv | 10.1007/s00066-012-0078-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1009812026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2693703261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-2dcbc68390a8896482eaaee8d8c737552c07c2ab298b79246d4619332206e5e33</originalsourceid><addsrcrecordid>eNp1kctqGzEUhkVoiB03D9BNEGTjLtToZl2WxeRSCHSTQHeDRnOcjDszmkpjEvdp-ix5smrqOIRAV5I4nz6dox-hT4x-YZTq80QpVYpQxkk-GiIO0JRJYQm19scHNKVMW6LZwkzQcUprSpmSVh6hCedCWs3EFP1ehrZ3sU6hw2GFE0CFy-j8w3Z4gOj6LQ4Rw9MAsXMNLsG1OLqqDvvqXNPnP1f_KC3H3Wdcd9gyi5vwSLL3J-5jSIMbAHvXeYi4d0MN3ZA-osOVaxKcvKwzdHd5cbu8Jjffr74tv94QLzQfCK986ZURljpjrJKGg3MApjJeC71YcE-1567k1pTacqkqqZgVgnOqYAFCzNB8582N_NpAGoq2Th6axnUQNqnIX2kN45SrjJ69Q9dhM04-UpwpYaUZKbajfJ4sRVgVfaxbF7cZGm262AVT5GCKMZhibOL0xbwpW6heb-yTyADfASmXunuIb5_-n_UvHo-YQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021639486</pqid></control><display><type>article</type><title>Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Goldner, G. ; Pötter, R. ; Battermann, J.J. ; Schmid, M.P. ; Kirisits, C. ; Sljivic, S. ; van Vulpen, M.</creator><creatorcontrib>Goldner, G. ; Pötter, R. ; Battermann, J.J. ; Schmid, M.P. ; Kirisits, C. ; Sljivic, S. ; van Vulpen, M.</creatorcontrib><description>Purpose
The aim of this analysis was to compare the biochemical no evidence of disease (bNED) rates in low-risk prostate cancer patients treated at two centers of excellence using different approaches: seed brachytherapy (BT) and external beam radiotherapy (EBRT).
Materials and methods
A total of 919 low-risk prostate cancer patients, treated from 1998–2008, were identified in the two databases. In Utrecht, 667 patients received I-125 BT applying a dose of 144 Gy. In Vienna, 252 patients were treated with EBRT, applying a local dose of 70 Gy in 82 patients and 74 Gy in 170 patients. bNED rates (Phoenix definition) were assessed.
Results
The median follow-up was 46 months (range 1–148 months). The 5-year actuarial bNED rates were 94% for BT patients and 88% for EBRT patients (p = 0.002)—84% for patients receiving 70 Gy and 91% for patients receiving 74 Gy, respectively. In the univariate analysis, patients receiving 70 Gy showed significantly worse outcome compared to BT (p = 0.001) and a difference close to significance compared to 74 Gy (p = 0.06). In the multivariate analysis including tumor stage, Gleason score, initial PSA, hormonal therapy, and dose, patients receiving 70 Gy EBRT showed significantly worse bNED rates compared to BT patients.
Conclusion
Low-risk prostate cancer patients receiving 74 Gy by EBRT show comparable biochemical control rates to patients receiving seed brachytherapy, whereas patients receiving 70 Gy show significantly worse outcome.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-012-0078-3</identifier><identifier>PMID: 22349713</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Aged ; Biomarkers, Tumor - blood ; Brachytherapy - methods ; Follow-Up Studies ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Oncology ; Original Article ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Radiotherapy ; Radiotherapy Dosage ; Radiotherapy, Conformal - methods</subject><ispartof>Strahlentherapie und Onkologie, 2012-04, Vol.188 (4), p.305-310</ispartof><rights>Urban & Vogel 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-2dcbc68390a8896482eaaee8d8c737552c07c2ab298b79246d4619332206e5e33</citedby><cites>FETCH-LOGICAL-c372t-2dcbc68390a8896482eaaee8d8c737552c07c2ab298b79246d4619332206e5e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00066-012-0078-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00066-012-0078-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22349713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldner, G.</creatorcontrib><creatorcontrib>Pötter, R.</creatorcontrib><creatorcontrib>Battermann, J.J.</creatorcontrib><creatorcontrib>Schmid, M.P.</creatorcontrib><creatorcontrib>Kirisits, C.</creatorcontrib><creatorcontrib>Sljivic, S.</creatorcontrib><creatorcontrib>van Vulpen, M.</creatorcontrib><title>Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><addtitle>Strahlenther Onkol</addtitle><description>Purpose
The aim of this analysis was to compare the biochemical no evidence of disease (bNED) rates in low-risk prostate cancer patients treated at two centers of excellence using different approaches: seed brachytherapy (BT) and external beam radiotherapy (EBRT).
Materials and methods
A total of 919 low-risk prostate cancer patients, treated from 1998–2008, were identified in the two databases. In Utrecht, 667 patients received I-125 BT applying a dose of 144 Gy. In Vienna, 252 patients were treated with EBRT, applying a local dose of 70 Gy in 82 patients and 74 Gy in 170 patients. bNED rates (Phoenix definition) were assessed.
Results
The median follow-up was 46 months (range 1–148 months). The 5-year actuarial bNED rates were 94% for BT patients and 88% for EBRT patients (p = 0.002)—84% for patients receiving 70 Gy and 91% for patients receiving 74 Gy, respectively. In the univariate analysis, patients receiving 70 Gy showed significantly worse outcome compared to BT (p = 0.001) and a difference close to significance compared to 74 Gy (p = 0.06). In the multivariate analysis including tumor stage, Gleason score, initial PSA, hormonal therapy, and dose, patients receiving 70 Gy EBRT showed significantly worse bNED rates compared to BT patients.
Conclusion
Low-risk prostate cancer patients receiving 74 Gy by EBRT show comparable biochemical control rates to patients receiving seed brachytherapy, whereas patients receiving 70 Gy show significantly worse outcome.</description><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Brachytherapy - methods</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiotherapy</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Conformal - methods</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kctqGzEUhkVoiB03D9BNEGTjLtToZl2WxeRSCHSTQHeDRnOcjDszmkpjEvdp-ix5smrqOIRAV5I4nz6dox-hT4x-YZTq80QpVYpQxkk-GiIO0JRJYQm19scHNKVMW6LZwkzQcUprSpmSVh6hCedCWs3EFP1ehrZ3sU6hw2GFE0CFy-j8w3Z4gOj6LQ4Rw9MAsXMNLsG1OLqqDvvqXNPnP1f_KC3H3Wdcd9gyi5vwSLL3J-5jSIMbAHvXeYi4d0MN3ZA-osOVaxKcvKwzdHd5cbu8Jjffr74tv94QLzQfCK986ZURljpjrJKGg3MApjJeC71YcE-1567k1pTacqkqqZgVgnOqYAFCzNB8582N_NpAGoq2Th6axnUQNqnIX2kN45SrjJ69Q9dhM04-UpwpYaUZKbajfJ4sRVgVfaxbF7cZGm262AVT5GCKMZhibOL0xbwpW6heb-yTyADfASmXunuIb5_-n_UvHo-YQw</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Goldner, G.</creator><creator>Pötter, R.</creator><creator>Battermann, J.J.</creator><creator>Schmid, M.P.</creator><creator>Kirisits, C.</creator><creator>Sljivic, S.</creator><creator>van Vulpen, M.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients</title><author>Goldner, G. ; Pötter, R. ; Battermann, J.J. ; Schmid, M.P. ; Kirisits, C. ; Sljivic, S. ; van Vulpen, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-2dcbc68390a8896482eaaee8d8c737552c07c2ab298b79246d4619332206e5e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Brachytherapy - methods</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiotherapy</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Conformal - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldner, G.</creatorcontrib><creatorcontrib>Pötter, R.</creatorcontrib><creatorcontrib>Battermann, J.J.</creatorcontrib><creatorcontrib>Schmid, M.P.</creatorcontrib><creatorcontrib>Kirisits, C.</creatorcontrib><creatorcontrib>Sljivic, S.</creatorcontrib><creatorcontrib>van Vulpen, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldner, G.</au><au>Pötter, R.</au><au>Battermann, J.J.</au><au>Schmid, M.P.</au><au>Kirisits, C.</au><au>Sljivic, S.</au><au>van Vulpen, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><stitle>Strahlenther Onkol</stitle><addtitle>Strahlenther Onkol</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>188</volume><issue>4</issue><spage>305</spage><epage>310</epage><pages>305-310</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>Purpose
The aim of this analysis was to compare the biochemical no evidence of disease (bNED) rates in low-risk prostate cancer patients treated at two centers of excellence using different approaches: seed brachytherapy (BT) and external beam radiotherapy (EBRT).
Materials and methods
A total of 919 low-risk prostate cancer patients, treated from 1998–2008, were identified in the two databases. In Utrecht, 667 patients received I-125 BT applying a dose of 144 Gy. In Vienna, 252 patients were treated with EBRT, applying a local dose of 70 Gy in 82 patients and 74 Gy in 170 patients. bNED rates (Phoenix definition) were assessed.
Results
The median follow-up was 46 months (range 1–148 months). The 5-year actuarial bNED rates were 94% for BT patients and 88% for EBRT patients (p = 0.002)—84% for patients receiving 70 Gy and 91% for patients receiving 74 Gy, respectively. In the univariate analysis, patients receiving 70 Gy showed significantly worse outcome compared to BT (p = 0.001) and a difference close to significance compared to 74 Gy (p = 0.06). In the multivariate analysis including tumor stage, Gleason score, initial PSA, hormonal therapy, and dose, patients receiving 70 Gy EBRT showed significantly worse bNED rates compared to BT patients.
Conclusion
Low-risk prostate cancer patients receiving 74 Gy by EBRT show comparable biochemical control rates to patients receiving seed brachytherapy, whereas patients receiving 70 Gy show significantly worse outcome.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22349713</pmid><doi>10.1007/s00066-012-0078-3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2012-04, Vol.188 (4), p.305-310 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1009812026 |
| source | MEDLINE; Springer Online Journals |
| subjects | Aged Biomarkers, Tumor - blood Brachytherapy - methods Follow-Up Studies Humans Iodine Radioisotopes - therapeutic use Male Medicine Medicine & Public Health Middle Aged Neoplasm Grading Neoplasm Staging Oncology Original Article Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Radiotherapy Radiotherapy Dosage Radiotherapy, Conformal - methods |
| title | Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T18%3A15%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20seed%20brachytherapy%20or%20external%20beam%20radiotherapy%20(70%C2%A0Gy%20or%2074%C2%A0Gy)%20in%20919%20low-risk%20prostate%20cancer%20patients&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Goldner,%20G.&rft.date=2012-04-01&rft.volume=188&rft.issue=4&rft.spage=305&rft.epage=310&rft.pages=305-310&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-012-0078-3&rft_dat=%3Cproquest_cross%3E2693703261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1021639486&rft_id=info:pmid/22349713&rfr_iscdi=true |